Latest period
$9.45B
YoY change
+10.7%
5Y CAGR
+8.7%
Peak year (2025)
$9.30B
Latest annual
$9.30B
Total Liabilities history chart for Regeneron Pharmaceuticals (REGN) from 1990 to 2025
Latest: $9.30B
Total Liabilities growth chart for Regeneron Pharmaceuticals (REGN) from 1990 to 2025
Latest: +10.7%
Total Liabilities history table for Regeneron Pharmaceuticals (REGN) from 1990 to 2025
| 2025 | $9.30B | +10.7% | +$896.00M | ||
| 2024 | $8.41B | +18.3% | +$1.30B | ||
| 2023 | $7.11B | +8.5% | +$556.60M | ||
| 2022 | $6.55B | -1.7% | −$115.50M | ||
| 2021 | $6.67B | +8.6% | +$528.00M | ||
| 2020 | $6.14B | +65.2% | +$2.42B | ||
| 2019 | $3.72B | +24.8% | +$738.30M | ||
| 2018 | $2.98B | +13.6% | +$356.99M | ||
| 2017 | $2.62B | +3.8% | +$95.99M | ||
| 2016 | $2.52B | +29.2% | +$569.93M | ||
| 2015 | $1.95B | +47.0% | +$624.79M | ||
| 2014 | $1.33B | +33.1% | +$330.56M | ||
| 2013 | $998.94M | +19.6% | +$163.83M | ||
| 2012 | $835.11M | -0.3% | −$2.75M | ||
| 2011 | $837.85M | +49.2% | +$276.23M | ||
| 2010 | $561.62M | +63.1% | +$217.18M | ||
| 2009 | $344.44M | +37.1% | +$93.25M | ||
| 2008 | $251.19M | -47.2% | −$224.81M | ||
| 2007 | $475.99M | +29.2% | +$107.53M | ||
| 2006 | $368.47M | +19.1% | +$58.97M | ||
| 2005 | $309.50M | +6.5% | +$18.93M | ||
| 2004 | $290.56M | -15.0% | −$51.35M | ||
| 2003 | $341.91M | +39.2% | +$96.32M | ||
| 2002 | $245.59M | +7.2% | +$16.55M | ||
| 2001 | $229.04M | +776.1% | +$202.90M | ||
| 2000 | $26.14M | -4.9% | −$1.36M | ||
| 1999 | $27.50M | +7.0% | +$1.80M | ||
| 1998 | $25.70M | -12.9% | −$3.80M | ||
| 1997 | $29.50M | -3.9% | −$1.20M | ||
| 1996 | $30.70M | +18.5% | +$4.80M | ||
| 1995 | $25.90M | -4.4% | −$1.20M | ||
| 1994 | $27.10M | +41.1% | +$7.90M | ||
| 1993 | $19.20M | +79.4% | +$8.50M | ||
| 1992 | $10.70M | +37.2% | +$2.90M | ||
| 1991 | $7.80M | -40.9% | −$5.40M | ||
| 1990 | $13.20M | — | — |
- 2025$9.30B+10.7%
- 2024$8.41B+18.3%
- 2023$7.11B+8.5%
- 2022$6.55B-1.7%
- 2021$6.67B+8.6%
- 2020$6.14B+65.2%
- 2019$3.72B+24.8%
- 2018$2.98B+13.6%
- 2017$2.62B+3.8%
- 2016$2.52B+29.2%
- 2015$1.95B+47.0%
- 2014$1.33B+33.1%
- 2013$998.94M+19.6%
- 2012$835.11M-0.3%
- 2011$837.85M+49.2%
- 2010$561.62M+63.1%
- 2009$344.44M+37.1%
- 2008$251.19M-47.2%
- 2007$475.99M+29.2%
- 2006$368.47M+19.1%
- 2005$309.50M+6.5%
- 2004$290.56M-15.0%
- 2003$341.91M+39.2%
- 2002$245.59M+7.2%
- 2001$229.04M+776.1%
- 2000$26.14M-4.9%
- 1999$27.50M+7.0%
- 1998$25.70M-12.9%
- 1997$29.50M-3.9%
- 1996$30.70M+18.5%
- 1995$25.90M-4.4%
- 1994$27.10M+41.1%
- 1993$19.20M+79.4%
- 1992$10.70M+37.2%
- 1991$7.80M-40.9%
- 1990$13.20M—
Total Liabilities values are taken from Regeneron Pharmaceuticals's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Total Liabilities at Regeneron Pharmaceuticals (REGN)
According to Regeneron Pharmaceuticals's latest reported financial statements, the company's latest reported total liabilities is $9.45B. Total liabilities sum everything the company owes at the end of each reporting period — accounts payable, accrued expenses, debt, lease obligations, and other claims — as filed on the balance sheet. Compare with total assets and total equity for solvency context.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
The 2025 reading of Regeneron Pharmaceuticals (REGN) total liabilities is $9.30B – grew 10.7% year-over-year.
Looking at the 2020–2025 (5 years) stretch, Regeneron Pharmaceuticals total liabilities compounded at +8.7% per year, with mixed annual results across the window.
Across the available history, total liabilities reached its high of $9.30B in 2025 and its low of $7.80M in 1991.
Regeneron Pharmaceuticals Total Liabilities by Year
Regeneron Pharmaceuticals Total Liabilities 2025: $9.30B
Regeneron Pharmaceuticals posted total liabilities of $9.30B in 2025, grew 10.7% from 2024. This figure represents the highest annual value in the available history.
Regeneron Pharmaceuticals Total Liabilities 2024: $8.41B
In 2024, Regeneron Pharmaceuticals reported total liabilities of $8.41B, grew 18.3% from 2023.
Regeneron Pharmaceuticals Total Liabilities 2023: $7.11B
Regeneron Pharmaceuticals total liabilities in 2023 was $7.11B, grew 8.5% from 2022.
Regeneron Pharmaceuticals Total Liabilities 2022: $6.55B
2022's total liabilities for Regeneron Pharmaceuticals came in at $6.55B, edged down 1.7% below 2021.
Regeneron Pharmaceuticals Total Liabilities 2021: $6.67B
Regeneron Pharmaceuticals total liabilities in 2021 was $6.67B.
See more financial history for Regeneron Pharmaceuticals (REGN).
Sector peers by Total Liabilities
Healthcare peers of Regeneron Pharmaceuticals (REGN), ranked by their latest total liabilities
| $207.88B | |
| $137.19B | |
| $117.67B | |
| $85.94B | |
| $84.20B | |
| $81.93B | |
| $65.36B | |
| $54.86B |
- $207.88B
- $137.19B
- $117.67B
- $85.94B
- $84.20B
- $81.93B
- $65.36B
- $54.86B
Frequently asked questions
Regeneron Pharmaceuticals (REGN) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation